Today, Valeant Pharmaceuticals Intl’s (VRX) Sector Perform Rating Reaffirm at Royal Bank Of Canada

Today, Valeant Pharmaceuticals Intl’s (VRX) Sector Perform Rating Reaffirm at Royal Bank Of Canada

Royal Bank Of Canada reissued their sector perform rating on shares of Valeant Pharmaceuticals Intl Inc (TSE:VRX) (NYSE:VRX) in a research report released on Monday, StockTargetPrices.com reports. Royal Bank Of Canada currently has a C$39.00 price target on the specialty pharmaceutical company’s stock.

Other research analysts have also recently issued research reports about the stock. TD Securities reaffirmed a buy rating and issued a C$38.00 price target on shares of Valeant Pharmaceuticals Intl in a report on Wednesday, August 10th. Scotiabank decreased their price target on shares of Valeant Pharmaceuticals Intl from C$32.00 to C$17.00 and set a sector perform rating on the stock in a report on Wednesday, November 9th.

Shares of Valeant Pharmaceuticals Intl (TSE:VRX) opened at 23.47 on Monday. The firm’s market cap is $8.16 billion. Valeant Pharmaceuticals Intl has a 12-month low of $18.41 and a 12-month high of $165.77. The company’s 50 day moving average price is $26.29 and its 200 day moving average price is $31.45.

Valeant Pharmaceuticals Intl Company Profile

Related posts

Leave a Comment